Wisconsin Alumni Research Foundation

Therapeutics & Vaccines
Therapeutics Vaccines
HYDROGEL COMPOSITIONS COMPRISING GASDERMIN D AND AN ESCRT INHIBITOR AND METHODS OF USE THEREOF
WARF: P220290US02

Inventors: Quanyin Hu, Zhaoting Li


The Invention
UW-Madison researchers have developed a novel approach for enhancing pyroptosis, which could prove beneficial in treating cancer. The inventors combine intracellular delivery of gasdermin with a small molecule that interferes with membrane repair in a single hydrogel nanoparticle. The gasdermin is delivered using a bacterial based vector (VNP-GD) and a calcium chelator (EI) is adhered to a nanoparticle (EI-NP). Calcium chelation blocks influx-triggered ESCRT III-dependent membrane repair. A biodegradable hydrogel matrix is used as a carrier to deliver and sustainably release the VNP-GD and EI-NP. 
Key Benefits
  • Platform delivery method
  • Compatible with a range of therapeutic modalities
  • Sustainable release
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847

WARF